Top

Journal of Interventional Cardiac Electrophysiology

Published in:

01-06-2015 | REVIEWS

Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy

Authors: Abhishek Bose, Quynh A. Truong, Jagmeet P. Singh

Published in: Journal of Interventional Cardiac Electrophysiology | Issue 1/2015

Abstract

Circulating biomarkers related to inflammation, neurohormones, myocardial stress, and necrosis have been associated with commonly encountered arrhythmic disorders such as atrial fibrillation (AF) and more malignant processes including ventricular arrhythmias (VA) and sudden cardiac death (SCD). Both direct and indirect biomarkers implicated in the heart failure cascade have potential prognostic value in patients undergoing cardiac resynchronization therapy (CRT). This review will focus on the role of biomarkers in AF, history of SCD, and CRT with an emphasis to improve clinical risk assessment for arrhythmias and patient selection for device therapy. Notably, information obtained from biomarkers may supplement traditional diagnostic and imaging techniques, thus providing an additional benefit in the management of patients.

Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics, 69, 89–95.

Manolio, T. (2003). Novel risk markers and clinical practice. New England Journal of Medicine, 349, 1587–9.PubMed

Vitzthum, F., Behrens, F., Anderson, N. L., & Shaw, J. H. (2005). Proteomics: From basic research to diagnostic application. A review of requirements & needs. Journal of Proteome Research, 4, 1086–97.PubMed

Zolg, J. W., & Langen, H. (2004). How industry is approaching the search for new diagnostic markers and biomarkers. Molecular and Cellular Proteomics, 3, 345–54.PubMed

Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., American College of Cardiology Foundation/American Heart Association Task Force, et al. (2011). 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 123, 269–367.

Cairns, J. A., & Connolly, S. J. (1991). Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. Circulation, 84, 469–81.PubMed

Benjamin, E. J., Wolf, P. A., D’Agostino, R. B., Silbershatz, H., Kannel, W. B., & Levy, D. (1998). Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation, 98, 946–52.PubMed

Wilber, D. J., Pappone, C., Neuzil, P., De Paola, A., Marchlinski, F., Natale, A., ThermoCool AF Trial Investigators, et al. (2010). Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial. Journal of the American Medical Association, 303, 333–40.PubMed

Frustaci, A., Chimenti, C., Bellocci, F., Morgante, E., Russo, M. A., & Maseri, A. (1997). Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation, 96, 1180–4.PubMed

10.

Verheule, S., Wilson, E., Everett, T., Shanbhag, S., Golden, C., & Olgin, J. (2003). Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. Circulation, 107, 2615–22.PubMedCentralPubMed

11.

Kaireviciute, D., Blann, A. D., Balakrishnan, B., Lane, D. A., Patel, J. V., Uzdavinys, G., et al. (2010). Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. Thrombosis and Haemostasis, 104, 122–7.PubMed

12.

Bruins, P., te Velthuis, H., Yazdanbakhsh, A. P., Jansen, P. G., van Hardevelt, F. W., de Beaumont, E. M., et al. (1997). Activation of the complement system during and after cardiopulmonary bypass surgery: Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation, 96, 3542–8.PubMed

13.

Psychari, S. N., Apostolou, T. S., Sinos, L., Hamodraka, E., Liakos, G., & Kremastinos, D. T. (2005). Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. American Journal of Cardiology, 95, 764–7.PubMed

14.

Conway, D. S., Buggins, P., Hughes, E., & Lip, G. Y. (2004). Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. American Journal of Cardiology, 148, 462–6.

15.

Guo, Y., Lip, G. Y., & Apostolakis, S. (2012). Inflammation in atrial fibrillation. Journal of the American College of Cardiology, 60, 2263–70.PubMed

16.

Cheng, T., Wang, X. F., Hou, Y. T., & Zhang, L. (2012). Correlation between atrial fibrillation, serum amyloid protein A and other inflammatory cytokines. Molecular Medicine Reports, 6, 581–4.PubMed

17.

Watanabe, E., Arakawa, T., Uchiyama, T., Kodama, I., & Hishida, H. (2006). High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. International Journal of Cardiology, 108, 346–53.PubMed

18.

Dernellis, J., & Panaretou, M. (2001). C-reactive protein and paroxysmal atrial fibrillation: Evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiologica, 56, 375–80.PubMed

19.

Neuman, R. B., Bloom, H. L., Shukrullah, I., Darrow, L. A., Kleinbaum, D., Jones, D. P., et al. (2007). Oxidative stress markers are associated with persistent atrial fibrillation. Clinical Chemistry, 53, 1652–7.PubMedCentralPubMed

20.

Shimano, M., Shibata, R., Inden, Y., Yoshida, N., Uchikawa, T., Tsuji, Y., et al. (2009). Reactive oxidative metabolites are associated with atrial conduction disturbance in patients with atrial fibrillation. Heart Rhythm, 6, 935–40.PubMed

21.

Rudolph, V., Andrie, R. P., Rudolph, T. K., Friedrichs, K., Klinke, A., Hirsch-Hoffmann, B., et al. (2010). Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nature Medicine, 16, 470–4.PubMedCentralPubMed

22.

Richter, B., Gwechenberger, M., Socas, A., Zorn, G., Albinni, S., Marx, M., et al. (2012). Markers of oxidative stress after ablation of atrial fibrillation are associated with inflammation, delivered radiofrequency energy and early recurrence of atrial fibrillation. Clinical Research in Cardiology, 101, 217–25.PubMed

23.

Patlolla, V., Alsheikh-Ali, A. A., & Al-Ahmad, A. M. (2006). The renin–angiotensin system: A therapeutic target in atrial fibrillation. Pacing and Clinical Electrophysiology, 29, 1006–12.PubMed

24.

Iravanian, S., & Dudley, S. C., Jr. (2008). The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm, 5, S12–7.PubMedCentralPubMed

25.

Goette, A., Arndt, M., Rocken, C., Spiess, A., Staack, T., Geller, J. C., Huth, C., et al. (2000). Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation, 101, 2678–81.PubMed

26.

Goette, A., Staack, T., Rocken, C., Arndt, M., Geller, J. C., Huth, C., et al. (2000). Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. Journal of the American College of Cardiology, 35, 1669–77.PubMed

27.

Yin, Y., Dalal, D., Liu, Z., Wu, J., Liu, D., Lan, X., et al. (2006). Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. European Heart Journal, 27, 1841–6.PubMed

28.

Pedersen, O. D., Bagger, H., Kober, L., & Torp-Pedersen, C. (1999). Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation, 100, 376–80.PubMed

29.

Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., et al. (2005). Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Journal of the American College of Cardiology, 45, 712–9.PubMed

30.

Katan, M., Muller, B., & Christ-Crain, M. (2008). Copeptin: A new and promising diagnostic and prognostic marker. Critical Care, 12, 117.PubMedCentralPubMed

31.

Smith, J. G., Newton-Cheh, C., Almgren, P., Struck, J., Morgenthaler, N. G., Bergmann, A., et al. (2010). Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. Journal of the American College of Cardiology, 56, 1712–9.PubMedCentralPubMed

32.

Latini, R., Masson, S., Pirelli, S., Barlera, S., Pulitano, G., Carbonieri, E., GISSI-AF Investigators, et al. (2011). Circulating cardiovascular biomarkers in recurrent atrial fibrillation: Data from the GISSI-atrial fibrillation trial. Journal of Internal Medicine, 269, 160–71.PubMed

33.

Levin, E. R., Gardner, D. G., & Samson, W. K. (1998). Natriuretic peptides. New England Journal of Medicine, 33, 321–8.

34.

Masson, S., Latini, R., Anand, I. S., Barlera, S., Angelici, L., Vago, T., Val-HeFT Investigators, et al. (2008). Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). Journal of the American College of Cardiology, 52, 997–1003.PubMed

35.

Tang, W. H., Francis, G. S., Morrow, D. A., Newby, L. K., Cannon, C. P., Jesse, R. L., NACB Committee, et al. (2007). National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation, 116, e99–109.PubMed

36.

Ellinor, P. T., Low, A. F., Patton, K. K., Shea, M. A., & Macrae, C. A. (2005). Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. Journal of the American College of Cardiology, 45, 82–6.PubMed

37.

Hussein, A. A., Saliba, W. I., Martin, D. O., Shadman, M., Kanj, M., Bhargava, M., et al. (2011). Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation. Circulation, 123, 2077–82.PubMed

38.

Wang, T. J., Larson, M. G., Levy, D., Benjamin, E. J., Leip, E. P., Omland, T., et al. (2004). Plasma natriuretic peptide levels and the risk of cardiovascular events and death. New England Journal of Medicine, 350, 655–63.PubMed

39.

Patton, K. K., Ellinor, P. T., Heckbert, S. R., Christenson, R. H., DeFilippi, C., Gottdiener, J. S., et al. (2009). N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: The Cardiovascular Health Study. Circulation, 120, 1768–74.PubMedCentralPubMed

40.

Adlbrecht, C., Hulsmann, M., Strunk, G., Berger, R., Mörtl, D., Struck, J., et al. (2009). Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. European Journal of Heart Failure, 11, 361–6.PubMed

41.

Julian, M., Cacho, M., Garcia, M. A., Martín-Santamaría, S., de Pascual-Teresa, B., Ramos, A., et al. (2005). Adrenomedullin: A new target for the design of small molecule modulators with promising pharmacological activities. European Journal of Medicinal Chemistry, 40, 737–50.PubMed

42.

Wright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Jr., Ettinger, S. M., American College of Cardiology Foundation/American Heart Association Task Force on PracticeGuidelines, et al. (2011). 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. Journal of the American College of Cardiology, 57, 215–367.

43.

Range, F. T., Schafers, M., Acil, T., Schäfers, K. P., Kies, P., Paul, M., et al. (2007). Impaired myocardial perfusion and perfusion reserve associated with increased coronary resistance in persistent idiopathic atrial fibrillation. European Heart Journal, 28, 2223–30.PubMed

44.

van den Bos, E. J., Constantinescu, A. A., van Domburg, R. T., Akin, S., Jordaens, L. J., & Kofflard, M. J. (2011). Minor elevations in troponin I are associated with mortality and adverse cardiac events in patients with atrial fibrillation. European Heart Journal, 32, 611–7.PubMed

45.

Hijazi, Z., Oldgren, J., Andersson, U., Connolly, S. J., Ezekowitz, M. D., Hohnloser, S. H., et al. (2012). Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: A Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation, 125, 1605–16.PubMed

46.

Kallergis, E. M., Manios, E. G., Kanoupakis, E. M., Mavrakis, H. E., Arfanakis, D. A., Maliaraki, N. E., et al. (2008). Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: Biochemical assessment of collagen type-I turnover. Journal of the American College of Cardiology, 52, 211–5.PubMed

47.

Nagase, H., Visse, R., & Murphy, G. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research, 69, 562–73.PubMed

48.

Mukherjee, R., Herron, A. R., Lowry, A. S., Stroud, R. E., Stroud, M. R., Wharton, J. M., et al. (2006). Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. American Journal of Cardiology, 97, 532–7.PubMed

49.

Naji, F., Suran, D., Kanic, V., Vokac, D., & Sabovic, M. (2010). High homocysteine levels predict the recurrence of atrial fibrillation after successful electrical cardioversion. International Heart Journal, 51, 30–3.PubMed

50.

Kalogeropoulos, A. S., Tsiodras, S., Rigopoulos, A. G., Sakadakis, E. A., Triantafyllis, A., Kremastinos, D. T., et al. (2011). Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation. Biomed Central Cardiovascular Disorders, 11, 77.PubMedCentralPubMed

51.

Okumura, Y., Watanabe, I., Nakai, T., Ohkubo, K., Kofune, T., Kofune, M., et al. (2011). Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: Importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. Journal of Cardiovascular Electrophysiology, 22, 987–93.PubMed

52.

Ehrlich, J. R., Kaluzny, M., Baumann, S., Lehmann, R., & Hohnloser, S. H. (2011). Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation. Clinical Research in Cardiology, 100, 1029–36.PubMed

53.

Laterza, O. F., Price, C. P., & Scott, M. G. (2002). Cystatin C: An improved estimator of glomerular filtration rate? Clinical Chemistry, 48, 699–707.PubMed

54.

Alonso, A., Lopez, F. L., Matsushita, K., Loehr, L. R., Agarwal, S. K., Chen, L. Y., et al. (2011). Chronic kidney disease is associated with the incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Circulation, 123, 2946–53.PubMedCentralPubMed

55.

McManus, D. D., Corteville, D. C., Shlipak, M. G., Whooley, M. A., & Ix, J. H. (2009). Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). American Journal of Cardiology, 104, 1551–5.PubMedCentralPubMed

56.

Stecker, E. C., Reinier, K., Marijon, E., Narayanan, K., Teodorescu, C., Uy-Evanado, A., et al. (2014). Public health burden of sudden cardiac death in the United States. Circulation. Arrhythmia and Electrophysiology, 7, 212–7.PubMedCentralPubMed

57.

Albert, C. M., Chae, C. U., Grodstein, F., Rose, L. M., Rexrode, K. M., Ruskin, J. N., et al. (2003). Prospective study of sudden cardiac death among women in the United States. Circulation, 107, 2096–101.PubMed

58.

Nichol, G., Thomas, E., Callaway, C. W., Hedges, J., Powell, J. L., Aufderheide, T. P., Resuscitation Outcomes Consortium Investigators, et al. (2008). Regional variation in out-of-hospital cardiac arrest incidence and outcome. Journal of the American Medical Association, 300, 1423–31.PubMedCentralPubMed

59.

Moss, A. J., Zareba, W., Hall, W. J., Klein, H., Wilber, D. J., Cannom, D. S., Multicenter Automatic Defibrillator Implantation Trial II Investigators, et al. (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New England Journal of Medicine, 346, 877–83.PubMed

60.

Stecker, E. C., Vickers, C., Waltz, J., Socoteanu, C., John, B. T., Mariani, R., et al. (2006). Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: Two-year findings from the Oregon Sudden Unexpected Death Study. Journal of the American College of Cardiology, 47, 1161–6.PubMed

61.

Finn, A. V., Nakano, M., Narula, J., Kolodgie, F. D., & Virmani, R. (2010). Concept of vulnerable/unstable plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 1282–92.PubMed

62.

Burke, A. P., Farb, A., Malcom, G. T., Liang, Y. H., Smialek, J., & Virmani, R. (1997). Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. New England Journal of Medicine, 336, 1276–82.PubMed

63.

Albert, C. M., Ma, J., Rifai, N., Stampfer, M. J., & Ridker, P. M. (2002). Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation, 105, 2595–9.PubMed

64.

Biasucci, L. M., Bellocci, F., Landolina, M., Rordorf, R., Vado, A., Menardi, E., et al. (2012). Risk stratification of ischaemic patients with implantable cardioverter defibrillators by C-reactive protein and a multi-markers strategy: Results of the CAMI-GUIDE study. European Heart Journal, 33, 1344–50.PubMed

65.

Danesh, J., Kaptoge, S., Mann, A. G., Sarwar, N., Wood, A., Angleman, S. B., et al. (2008). Long-term interleukin-6 levels and subsequent risk of coronary heart disease: Two new prospective studies and a systematic review. Public Library of Science Medicine., 5, e78.PubMedCentralPubMed

66.

Empana, J. P., Jouven, X., Canoui-Poitrine, F., Luc, G., Tafflet, M., Haas, B., et al. (2010). C-reactive protein, interleukin 6, fibrinogen and risk of sudden death in European middle-aged men: The PRIME study. Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 2047–52.PubMed

67.

Sharma, O. P., Maheshwari, A., & Thaker, K. (1993). Myocardial sarcoidosis. Chest, 103, 253–8.PubMed

68.

Zipse, M. M., & Sauer, W. H. (2013). Electrophysiologic manifestations of cardiac sarcoidosis. Current Opinion in Pulmonary Medicine, 19, 485–92.PubMed

69.

Epstein, A. E., Dimarco, J. P., Ellenbogen, K. A., Estes, N. A., 3rd, Freedman, R. A., Gettes, L. S., et al. (2008). ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Journal of the American College of Cardiology, 51, e1–62.PubMed

70.

Rassi, A., Jr., Rassi, S. G., & Rassi, A. (2001). Sudden death in Chagas’ disease. Arquivos Brasileiros de Cardiologia, 76, 75–96.PubMed

71.

Tseng, Z. H., Secemsky, E. A., Dowdy, D., Vittinghoff, E., Moyers, B., Wong, J. K., et al. (2012). Sudden cardiac death in patients with human immunodeficiency virus infection. Journal of the American College of Cardiology, 59, 1891–6.PubMedCentralPubMed

72.

Tapanainen, J. M., Lindgren, K. S., Makikallio, T. H., Vuolteenaho, O., Leppaluoto, J., & Huikuri, H. V. (2004). Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. Journal of the American College of Cardiology, 43, 757–63.PubMed

73.

Berger, R., Huelsman, M., Strecker, K., Bojic, A., Moser, P., Stanek, B., & Pacher, R. (2002). B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation, 105, 2392–7.PubMed

74.

Korngold, E. C., Januzzi, J. L., Jr., Gantzer, M. L., Moorthy, M. V., Cook, N. R., & Albert, C. M. (2009). Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women. Circulation, 119, 2868–76.PubMedCentralPubMed

75.

Patton, K. K., Sotoodehnia, N., DeFilippi, C., Siscovick, D. S., Gottdiener, J. S., & Kronmal, R. A. (2011). N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: The Cardiovascular Health Study. Heart Rhythm, 8, 228–33.PubMed

76.

Liu, Z., Cui, L., Wang, Y., & Guo, Y. (2006). Cardiac troponin I and ventricular arrhythmia in patients with chronic heart failure. European Journal of Clinical Investigation, 36, 466–72.PubMed

77.

Uusimaa, P., Risteli, J., Niemela, M., Lumme, J., Ikäheimo, M., Jounela, A., et al. (1997). Collagen scar formation after acute myocardial infarction: Relationships to infarct size, left ventricular function, and coronary artery patency. Circulation, 96, 2565–72.PubMed

78.

Querejeta, R., Varo, N., Lopez, B., Larman, M., Artiñano, E., Etayo, J. C., et al. (2000). Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation, 101, 1729–35.PubMed

79.

Spach, M. S., & Boineau, J. P. (1997). Microfibrosis produces electrical load variations due to loss of side-to-side cell connections: A major mechanism of structural heart disease arrhythmias. Pacing and Clinical Electrophysiology, 20, 397–413.PubMed

80.

Flevari, P., Theodorakis, G., Leftheriotis, D., Kroupis, C., Kolokathis, F., Dima, K., et al. (2012). Serum markers of deranged myocardial collagen turnover: Their relation to malignant ventricular arrhythmias in cardioverter-defibrillator recipients with heart failure. American Heart Journal, 164, 530–7.PubMed

81.

Nygard, O., Nordrehaug, J. E., Refsum, H., Ueland, P. M., Farstad, M., & Vollset, S. E. (1997). Plasma homocysteine levels and mortality in patients with coronary artery disease. New England Journal of Medicine, 337, 230–6.PubMed

82.

Burke, A. P., Fonseca, V., Kolodgie, F., Zieske, A., Fink, L., & Virmani, R. (2002). Increased serum homocysteine and sudden death resulting from coronary atherosclerosis with fibrous plaques. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 1936–41.PubMed

83.

Deo, R., Sotoodehnia, N., Katz, R., Sarnak, M. J., Fried, L. F., Chonchol, M., et al. (2010). Cystatin C and sudden cardiac death risk in the elderly. Circulation. Cardiovascular Quality and Outcomes, 3, 159–64.PubMedCentralPubMed

84.

Soloff, L. A. (1970). Arrhythmias following infusions of fatty acids. American Heart Journal, 80, 671–4.PubMed

85.

Jouven, X., Charles, M. A., Desnos, M., & Ducimetiere, P. (2001). Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation, 104, 756–61.PubMed

86.

Pilz, S., Scharnagl, H., Tiran, B., Wellnitz, B., Seelhorst, U., Boehm, B. O., et al. (2007). Elevated plasma free fatty acids predict sudden cardiac death: A 6.85-year follow-up of 3315 patients after coronary angiography. European Heart Journal, 28, 2763–9.PubMed

87.

Abraham, W. T., Fisher, W. G., Smith, A. L., Delurgio, D. B., Leon, A. R., Loh, E., MIRACLE Study Group, et al. (2002). Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. New England Journal of Medicine, 346, 1845–53.PubMed

88.

Bristow, M. R., Saxon, L. A., Boehmer, J., Krueger, S., Kass, D. A., De Marco, T., Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators, et al. (2004). Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New England Journal of Medicine, 350, 2140–50.PubMed

89.

Young, J. B., Abraham, W. T., Smith, A. L., Leon, A. R., Lieberman, R., Wilkoff, B., et al. (2003). Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. Journal of the American Medical Association, 289, 2685–94.PubMed

90.

Vasan, R. S., Sullivan, L. M., Roubenoff, R., Dinarello, C. A., Harris, T., Benjamin, E. J., et al. (2003). Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation, 107, 1486–91.PubMed

91.

Lappegard, K. T., & Bjornstad, H. (2006). Anti-inflammatory effect of cardiac resynchronization therapy. Pacing and Clinical Electrophysiology, 29, 753–8.PubMed

92.

Theodorakis, G. N., Flevari, P., Kroupis, C., Adamopoulos, S., Livanis, E. G., Kostopoulou, A., et al. (2006). Antiinflammatory effects of cardiac resynchronization therapy in patients with chronic heart failure. Pacing and Clinical Electrophysiology, 29, 255–61.PubMed

93.

Rubaj, A., Rucinski, P., Rejdak, K., Oleszczak, K., Duma, D., Grieb, P., et al. (2006). Biventricular versus right ventricular pacing decreases immune activation and augments nitric oxide production in patients with chronic heart failure. European Journal of Heart Failure, 8, 615–20.PubMed

94.

Michelucci, A., Ricciardi, G., Sofi, F., Gori, A. M., Pirolo, F., Pieragnoli, P., et al. (2007). Relation of inflammatory status to major adverse cardiac events and reverse remodeling in patients undergoing cardiac resynchronization therapy. Journal of Cardiac Failure, 13, 207–10.PubMed

95.

Januzzi, J. L., Jr., Camargo, C. A., Anwaruddin, S., Baggish, A. L., Chen, A. A., Krauser, D. G., et al. (2005). The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. American Journal of Cardiology, 95, 948–54.PubMed

96.

Maisel, A. S., McCord, J., Nowak, R. M., Hollander, J. E., Wu, A. H., Duc, P., et al. (2003). Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. Journal of the American College of Cardiology, 41, 2010–7.PubMed

97.

Jourdain, P., Jondeau, G., Funck, F., Gueffet, P., Le Helloco, A., Donal, E., et al. (2007). Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study. Journal of the American College of Cardiology, 49, 1733–9.PubMed

98.

Januzzi, J. L., Jr., Rehman, S. U., Mohammed, A. A., Bhardwaj, A., Barajas, L., Barajas, J., et al. (2011). Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. Journal of the American College of Cardiology, 58, 1881–9.PubMed

99.

Delgado, R. M., Palanichamy, N., Radovancevic, R., Vrtovec, B., & Radovancevic, B. (2006). Brain natriuretic peptide levels and response to cardiac resynchronization therapy in heart failure patients. Congestive Heart Failure, 12, 250–3.PubMed

100.

Lellouche, N., De Diego, C., Cesario, D. A., Vaseghi, M., Horowitz, B. N., Mahajan, A., et al. (2007). Usefulness of preimplantation B-type natriuretic peptide level for predicting response to cardiac resynchronization therapy. American Journal of Cardiology, 99, 242–6.PubMed

101.

Braun, M. U., Rauwolf, T., Zerm, T., Schulze, M., Schnabel, A., & Strasser, R. H. (2005). Long term biventricular resynchronisation therapy in advanced heart failure: Effect on neurohormones. Heart, 91, 601–5.PubMedCentralPubMed

102.

Fruhwald, F. M., Fahrleitner-Pammer, A., Berger, R., Leyva, F., Freemantle, N., Erdmann, E., et al. (2007). Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. European Heart Journal, 28, 1592–7.PubMed

103.

Berger, R., Shankar, A., Fruhwald, F., Fahrleitner-Pammer, A., Freemantle, N., Tavazzi, L., et al. (2009). Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: An analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study. European Heart Journal, 30, 2109–16.PubMed

104.

Smit, M. D., Maass, A. H., Hillege, H. L., Wiesfeld, A. C., Van Veldhuisen, D. J., & Van Gelder, I. C. (2011). Prognostic importance of natriuretic peptides and atrial fibrillation in patients receiving cardiac resynchronization therapy. European Journal of Heart Failure, 13, 543–50.PubMed

105.

Morales, M. A., Maltinti, M., Piacenti, M., Turchi, S., Giannessi, D., & Del, R. S. (2010). Adrenomedullin plasma levels predict left ventricular reverse remodeling after cardiac resynchronization therapy. Pacing and Clinical Electrophysiology, 33, 865–72.PubMed

106.

Horwich, T. B., Patel, J., MacLellan, W. R., & Fonarow, G. C. (2003). Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation, 108, 833–8.PubMed

107.

Omland, T., de Lemos, J. A., Sabatine, M. S., Christophi, C. A., Rice, M. M., Jablonski, K. A., Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial Investigators, et al. (2009). A sensitive cardiac troponin T assay in stable coronary artery disease. New England Journal of Medicine, 361, 2538–47.PubMedCentralPubMed

108.

Aarones, M., Gullestad, L., Aakhus, S., Ueland, T., Skaardal, R., Aass, H., et al. (2011). Prognostic value of cardiac troponin T in patients with moderate to severe heart failure scheduled for cardiac resynchronization therapy. American Heart Journal, 161, 1031–7.PubMed

109.

Spinale, F. G., Coker, M. L., Heung, L. J., Bond, B. R., Gunasinghe, H. R., Etoh, T., et al. (2000). A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation, 102, 1944–9.PubMed

110.

George, J., Patal, S., Wexler, D., Roth, A., Sheps, D., & Keren, G. (2005). Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. American Heart Journal, 150, 484–7.PubMed

111.

Hessel, M. H., Bleeker, G. B., Bax, J. J., Henneman, M. M., den Adel, B., Klok, M., et al. (2007). Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. European Journal of Heart Failure, 9, 1058–63.PubMed

112.

Tolosana, J. M., Mont, L., Sitges, M., Berruezo, A., Delgado, V., Vidal, B., et al. (2010). Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): An independent predictor of poor response to cardiac resynchronization therapy. European Journal of Heart Failure, 12, 492–8.PubMedCentralPubMed

113.

Querejeta, R., Lopez, B., Gonzalez, A., Sánchez, E., Larman, M., Martínez Ubago, J. L., et al. (2004). Increased collagen type I synthesis in patients with heart failure of hypertensive origin: Relation to myocardial fibrosis. Circulation, 110, 1263–8.PubMed

114.

Burlew, B. S., & Weber, K. T. (2002). Cardiac fibrosis as a cause of diastolic dysfunction. Herz Cardiovascular Diseases, 27, 92–8.

115.

Garcia-Bolao, I., Macias, A., Lopez, B., González, A., Gavira, J. J., Azcárate, P., et al. (2006). A biomarker of myocardial fibrosis predicts long-term response to cardiac resynchronization therapy. Journal of the American College of Cardiology, 47, 2335–7.PubMed

116.

Garcia-Bolao, I., Lopez, B., Macias, A., Gavira, J. J., Azcarate, P., & Diez, J. (2008). Impact of collagen type I turnover on the long-term response to cardiac resynchronization therapy. European Heart Journal, 29, 898–906.PubMed

117.

Sharma, U. C., Pokharel, S., van Brakel, T. J., van Berlo, J. H., Cleutjens, J. P., Schroen, B., et al. (2004). Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation, 110, 3121–8.PubMed

118.

de Boer, R. A., Lok, D. J., Jaarsma, T., van der Meer, P., Voors, A. A., Hillege, H. L., et al. (2011). Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Annals of Medicine, 43, 60–8.PubMedCentralPubMed

119.

Lopez-Andres, N., Rossignol, P., Iraqi, W., Fay, R., Nuée, J., Ghio, S., et al. (2012). Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: Insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. European Journal of Heart Failure, 14, 74–81.PubMed

120.

Hillege, H. L., Nitsch, D., Pfeffer, M. A., Swedberg, K., McMurray, J. J., Yusuf, S., Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators, et al. (2006). Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation, 113, 671–8.PubMed

121.

Goldenberg, I., Moss, A. J., McNitt, S., Barsheshet, A., Gray, D., Andrews, M. L., et al. (2010). Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT). Heart Rhythm, 7, 1777–82.PubMed

122.

Yamamoto, T., Shimano, M., Inden, Y., Miyata, S., Inoue, Y., Yoshida, N., et al. (2013). Cystatin C as a predictor of mortality and cardiovascular morbidity after cardiac resynchronization therapy. Circulation Journal, 77, 2751–6.PubMed

123.

Kempf, T., von Haehling, S., Peter, T., Allhoff, T., Cicoira, M., Doehner, W., et al. (2007). Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. Journal of the American College of Cardiology, 50, 1054–60.PubMed

124.

Foley, P. W., Stegemann, B., Ng, K., Ramachandran, S., Proudler, A., Frenneaux, M. P., et al. (2009). Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. European Heart Journal, 30, 2749–57.PubMedCentralPubMed

125.

Monceau, V., Belikova, Y., Kratassiouk, G., Charue, D., Camors, E., Communal, C., et al. (2004). Externalization of endogenous annexin A5 participates in apoptosis of rat cardiomyocytes. Cardiovascular Research, 64, 496–506.PubMed

126.

Ravassa, S., Gonzalez, A., Lopez, B., Beaumont, J., Querejeta, R., Larman, M., et al. (2007). Upregulation of myocardial Annexin A5 in hypertensive heart disease: Association with systolic dysfunction. European Heart Journal, 28, 2785–91.PubMed

127.

Ravassa, S., Garcia-Bolao, I., Zudaire, A., Macías, A., Gavira, J. J., Beaumont, J., et al. (2010). Cardiac resynchronization therapy-induced left ventricular reverse remodelling is associated with reduced plasma annexin A5. Cardiovascular Research, 88, 304–13.PubMed

128.

Lund, S. A., Giachelli, C. M., & Scatena, M. (2009). The role of osteopontin in inflammatory processes. Journal of Cell Communication and Signaling, 3, 311–22.PubMedCentralPubMed

129.

Rosenberg, M., Zugck, C., Nelles, M., Juenger, C., Frank, D., Remppis, A., et al. (2008). Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circulation. Heart Failure, 1, 43–9.PubMed

130.

Francia, P., Balla, C., Ricotta, A., Uccellini, A., Frattari, A., Modestino, A., et al. (2011). Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure. International Journal of Cardiology, 153, 306–10.PubMed

131.

Truong, Q. A., Januzzi, J. L., Szymonifka, J., Thai, W. E., Wai, B., Lavender, Z., et al. (2014). Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: The BIOCRT study. Heart Rhythm, 11, 2167–75.PubMed

Title: Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy
Authors: Abhishek Bose
Quynh A. Truong
Jagmeet P. Singh
Publication date: 01-06-2015
Publisher: Springer US
Published in: Journal of Interventional Cardiac Electrophysiology / Issue 1/2015
Print ISSN: 1383-875X
Electronic ISSN: 1572-8595
DOI: https://doi.org/10.1007/s10840-015-9982-7

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Left atrial appendage occlusion for prevention of stroke in nonvalvular atrial fibrillation: a meta-analysis

Ischemic necrosis of the left atrial appendage at autopsy 4 weeks following epicardial suture ligation via a sub-xiphoid approach (LARIAT)

A prospective study of anxiety in ICD patients with a pilot randomized controlled trial of cognitive behavioral therapy for patients with moderate to severe anxiety

The effect of C-reactive protein reduction with a highly specific antisense oligonucleotide on atrial fibrillation assessed using beat-to-beat pacemaker Holter follow-up

Erratum to: A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers

Common sense or evidence: an optimal place for right and left ventricular leads?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page